Tag: Gp iib iiia inhibitors

Glycoprotein (GP) IIb/IIIa inhibitors are a potent class of antiplatelet agents used to treat acute coronary syndromes (ACS), with studies showing they can reduce the 30-day rates of death or myocardial infarction [1.5.2, 1.5.4]. So, what are the examples of GP IIb-IIIa inhibitors and how do they work?

Intravenous (IV) antiplatelet therapy is a critical component of treatment for several acute cardiac conditions, providing a rapid-acting solution to prevent dangerous blood clots. While many antiplatelet medications are taken orally, the three primary IV antiplatelet drugs—abciximab, eptifibatide, and tirofiban—are powerful glycoprotein (GP) IIb/IIIa inhibitors used in a hospital setting for immediate and profound antiplatelet effects. These potent agents are typically administered during percutaneous coronary intervention (PCI) and for certain cases of acute coronary syndrome (ACS) to quickly inhibit platelet aggregation and reduce the risk of heart attack and other ischemic events.